HRP20100209T1 - Makrociklički inhibitori virusa hepatitisa c - Google Patents

Makrociklički inhibitori virusa hepatitisa c Download PDF

Info

Publication number
HRP20100209T1
HRP20100209T1 HR20100209T HRP20100209T HRP20100209T1 HR P20100209 T1 HRP20100209 T1 HR P20100209T1 HR 20100209 T HR20100209 T HR 20100209T HR P20100209 T HRP20100209 T HR P20100209T HR P20100209 T1 HRP20100209 T1 HR P20100209T1
Authority
HR
Croatia
Prior art keywords
compound according
c6alkyl
image
hydrogen
alkyl
Prior art date
Application number
HR20100209T
Other languages
English (en)
Croatian (hr)
Inventor
Jean-Marie Bernard Raboisson Pierre
Augustinus De Kock Herman
Hu Lili
Alan Simmen Kenneth
Charlotta Lindquist Karin
Stefan Lindstr�m Mats
Karin Gertrud Linnea Belfrage Anna
J�rgen W�hling Horst
Magnus Nilsson Karl
Bertil Samuelsson Bengt
Annica Kristina Rosenquist Asa
Crister Sahlberg Sven
Kristian Wallberg Hans
Cecilia Kahnberg Pia
Olof Classon Bj�rn
Original Assignee
Medivir Ab
Tibotec Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37708968&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20100209(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medivir Ab, Tibotec Pharmaceuticals filed Critical Medivir Ab
Publication of HRP20100209T1 publication Critical patent/HRP20100209T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
    • C07D245/04—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
HR20100209T 2005-07-29 2006-07-28 Makrociklički inhibitori virusa hepatitisa c HRP20100209T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05107057 2005-07-29
EP06113097 2006-04-25
PCT/EP2006/064822 WO2007014927A2 (fr) 2005-07-29 2006-07-28 Inhibiteurs macrocycliques du virus de l'hepatite c

Publications (1)

Publication Number Publication Date
HRP20100209T1 true HRP20100209T1 (hr) 2010-05-31

Family

ID=37708968

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20100209T HRP20100209T1 (hr) 2005-07-29 2006-07-28 Makrociklički inhibitori virusa hepatitisa c

Country Status (31)

Country Link
US (1) US7659245B2 (fr)
EP (1) EP1912981B1 (fr)
JP (1) JP5230418B2 (fr)
KR (1) KR101083631B1 (fr)
AP (1) AP2585A (fr)
AR (1) AR057702A1 (fr)
AT (1) ATE455775T1 (fr)
AU (1) AU2006274866B2 (fr)
BR (1) BRPI0614153A2 (fr)
CA (1) CA2617103C (fr)
CY (1) CY1110008T1 (fr)
DE (1) DE602006011905D1 (fr)
DK (1) DK1912981T3 (fr)
EA (1) EA014188B1 (fr)
ES (1) ES2339702T3 (fr)
GT (1) GT200600343A (fr)
HR (1) HRP20100209T1 (fr)
IL (1) IL188320A (fr)
ME (1) ME01454B (fr)
MY (1) MY151026A (fr)
NO (1) NO20081075L (fr)
NZ (1) NZ564540A (fr)
PE (1) PE20070343A1 (fr)
PL (1) PL1912981T3 (fr)
PT (1) PT1912981E (fr)
RS (1) RS51227B (fr)
SI (1) SI1912981T1 (fr)
SV (1) SV2008002641A (fr)
TW (1) TWI387597B (fr)
UY (1) UY29704A1 (fr)
WO (1) WO2007014927A2 (fr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
PL1713822T3 (pl) 2004-01-30 2010-08-31 Medivir Ab Inhibitory proteazy serynowej HCV NS-3
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
TW200745061A (en) 2005-07-29 2007-12-16 Tibotec Pharm Ltd Macrocylic inhibitors of hepatitis C virus
JO2768B1 (en) * 2005-07-29 2014-03-15 تيبوتيك فارماسيوتيكالز ليمتد Large cyclic inhibitors of hepatitis C virus
RU2436787C2 (ru) 2005-07-29 2011-12-20 Тиботек Фармасьютикалз Лтд. Макроциклические ингибиторы вируса гепатита с
ES2356776T3 (es) 2005-10-11 2011-04-13 Intermune, Inc. Compuestos y métodos para inhibir la replicación del virus de la hepatitis.
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
RU2008152171A (ru) 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) Новые ингибиторы вирусной репликации гепатита с
US7935670B2 (en) 2006-07-11 2011-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
PT2041156E (pt) 2006-07-13 2014-02-21 Achillion Pharmaceuticals Inc Péptidos 4-amino-4-oxobutanoil como inibidores da replicação viral
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
BRPI0718798A2 (pt) * 2006-11-17 2013-12-03 Tibotec Pharm Ltd Inibidores macrocíclicos de vírus da hepatite c
DE602008001251D1 (de) * 2007-02-01 2010-06-24 Tibotec Pharm Ltd Verfahren und zwischenprodukte zur herstellung eines makrozyklischen proteasehemmers von hcv
CN101641349A (zh) * 2007-02-08 2010-02-03 泰博特克药品有限公司 嘧啶取代的大环抑制剂
ITMI20071616A1 (it) 2007-08-03 2009-02-04 Cosmo Spa Processo enzimatico per l'ottenimento di 17-alfa monoesteri del cortexolone e/o suoi 9,11-deidroderivati.
WO2009042668A2 (fr) * 2007-09-24 2009-04-02 Achillion Pharmaceuticals, Inc. Peptides contenant de l'urée en tant qu'inhibiteurs de la réplication virale
US8383583B2 (en) 2007-10-26 2013-02-26 Enanta Pharmaceuticals, Inc. Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
US8426360B2 (en) * 2007-11-13 2013-04-23 Enanta Pharmaceuticals, Inc. Carbocyclic oxime hepatitis C virus serine protease inhibitors
WO2009070692A1 (fr) 2007-11-29 2009-06-04 Enanta Pharmaceuticals, Inc. Inhibiteurs de sérine protéase de l'hépatite c macrocycliques, dérivés de la proline, substitués en c5
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
WO2009084695A1 (fr) 2007-12-28 2009-07-09 Carna Biosciences Inc. Dérivé de 2-aminoquinazoline
CN102015652A (zh) 2008-03-20 2011-04-13 益安药业 作为丙型肝炎病毒抑制剂的氟化大环化合物
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2300491B1 (fr) 2008-05-29 2016-01-06 Bristol-Myers Squibb Company Inhibiteurs du virus de l hépatite c
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2364309B1 (fr) 2008-12-10 2014-10-01 Achillion Pharmaceuticals, Inc. Nouveaux peptides 4-amino-4-oxobutanoyl utiles en tant qu'inhibiteurs de la réplication virale
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
PL2401272T3 (pl) 2009-02-27 2017-06-30 Janssen Pharmaceuticals, Inc. Amorficzna sól makrocyklicznego inhibitora HCV
TW201040181A (en) 2009-04-08 2010-11-16 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
NZ596546A (en) * 2009-05-29 2012-12-21 Syngenta Participations Ag Substituted quinazolines as fungicides
EP2461811B1 (fr) 2009-08-05 2016-04-20 Idenix Pharmaceuticals LLC. Inhibiteurs macrocycliques de la sérine protéase macrocyclique utiles contre les infections virales, en particulier le virus de l'hépatite c
EP2658859A4 (fr) 2010-12-30 2014-07-30 Enanta Pharm Inc Inhibiteurs macrocycliques de sérine protéase d'hépatite c
KR20140003521A (ko) 2010-12-30 2014-01-09 이난타 파마슈티칼스, 인코포레이티드 페난트리딘 매크로사이클릭 ｃ형 간염 세린 프로테아제 억제제
AR085352A1 (es) 2011-02-10 2013-09-25 Idenix Pharmaceuticals Inc Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP6170944B2 (ja) 2011-12-28 2017-07-26 ヤンセン・サイエンシズ・アイルランド・ユーシー Ｈｃｖ阻害剤としてのヘテロ−二環式誘導体
ES2664050T3 (es) * 2012-10-15 2018-04-18 Albemarle Corporation Procesos para la síntesis de la 2-amino-4,6-dimetoxibenzamida y otros compuestos de benzamida
EA025560B1 (ru) 2012-10-19 2017-01-30 Бристол-Майерс Сквибб Компани Ингибиторы вируса гепатита с
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014070964A1 (fr) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
WO2014071007A1 (fr) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
EP2914614B1 (fr) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
WO2014137869A1 (fr) 2013-03-07 2014-09-12 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
US9085607B2 (en) 2013-03-15 2015-07-21 Achillion Pharmaceuticals, Inc. ACH-0142684 sodium salt polymorph, composition including the same, and method of manufacture thereof
WO2014145507A1 (fr) 2013-03-15 2014-09-18 Achillion Pharmaceuticals, Inc. Procédé de fabrication d'un analogue cyclique de peptide de 4-amino-4-oxobutanoyle, inhibiteur de réplication virale et leurs intermédiaires
EP3089757A1 (fr) 2014-01-03 2016-11-09 AbbVie Inc. Formes galéniques antivirales solides
EP3108879A1 (fr) 2015-06-25 2016-12-28 Cassiopea S.p.A. Formulation à concentration élevée

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US6867185B2 (en) 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
AU2003223602B8 (en) 2002-04-11 2010-05-27 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis C virus NS3-NS4 protease
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
US20040180815A1 (en) * 2003-03-07 2004-09-16 Suanne Nakajima Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
CA2515216A1 (fr) * 2003-02-07 2004-08-26 Enanta Pharmaceuticals, Inc. Inhibiteurs macrocycliques de la serine protease de l'hepatite c
ES2320771T3 (es) * 2003-04-16 2009-05-28 Bristol-Myers Squibb Company Inhibidores peptidicos de isoquinolina macrociclicos del virus de la hepatitis c.
US7125845B2 (en) * 2003-07-03 2006-10-24 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis C serine protease inhibitors
RS20060197A (sr) * 2003-09-22 2008-09-29 Boehringer Ingelheim International Gmbh., Makrociklični peptidi koji su aktivni protiv hepatitisa c virusa
PL1713822T3 (pl) * 2004-01-30 2010-08-31 Medivir Ab Inhibitory proteazy serynowej HCV NS-3
RU2419619C2 (ru) * 2005-07-29 2011-05-27 Медивир Аб Макроциклические ингибиторы вируса гепатита с
US8012939B2 (en) * 2005-07-29 2011-09-06 Tibotec Pharmaceuticals Ltd. Co Macrocyclic inhibitors of hepatitis C virus
CN101273042B (zh) * 2005-07-29 2013-11-06 泰博特克药品有限公司 丙型肝炎病毒的大环抑制剂
PE20070211A1 (es) * 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c

Also Published As

Publication number Publication date
ES2339702T3 (es) 2010-05-24
IL188320A0 (en) 2008-04-13
CA2617103A1 (fr) 2007-02-08
RS51227B (sr) 2010-12-31
NO20081075L (no) 2008-04-25
NZ564540A (en) 2010-03-26
ME01454B (me) 2014-04-20
TW200745116A (en) 2007-12-16
EP1912981B1 (fr) 2010-01-20
PT1912981E (pt) 2010-04-16
IL188320A (en) 2014-07-31
DK1912981T3 (da) 2010-05-25
PE20070343A1 (es) 2007-05-12
CA2617103C (fr) 2015-01-06
PL1912981T3 (pl) 2010-07-30
ATE455775T1 (de) 2010-02-15
AP2585A (en) 2013-02-04
CY1110008T1 (el) 2015-01-14
DE602006011905D1 (de) 2010-03-11
JP2009502890A (ja) 2009-01-29
AR057702A1 (es) 2007-12-12
KR20080033475A (ko) 2008-04-16
BRPI0614153A2 (pt) 2011-03-15
KR101083631B1 (ko) 2011-11-16
EA014188B1 (ru) 2010-10-29
JP5230418B2 (ja) 2013-07-10
EP1912981A2 (fr) 2008-04-23
EA200800482A1 (ru) 2008-06-30
US20090118312A1 (en) 2009-05-07
SI1912981T1 (sl) 2010-05-31
WO2007014927A3 (fr) 2007-11-29
HK1116488A1 (en) 2008-12-24
TWI387597B (zh) 2013-03-01
AU2006274866B2 (en) 2012-04-12
UY29704A1 (es) 2007-05-31
GT200600343A (es) 2007-08-06
SV2008002641A (es) 2008-07-23
AU2006274866A1 (en) 2007-02-08
WO2007014927A2 (fr) 2007-02-08
US7659245B2 (en) 2010-02-09
MY151026A (en) 2014-03-31

Similar Documents

Publication Publication Date Title
HRP20100209T1 (hr) Makrociklički inhibitori virusa hepatitisa c
HRP20100048T1 (hr) Inhibitori hcv ns-3 serin proteaze
NO20081071L (no) Makrocykliske inhibitorer av hepatitt C virus
JP2013514359A5 (fr)
EP2041159B8 (fr) Composes macrocycliques en tant qu'agents antiviraux
HRP20181075T1 (hr) Makrociklični inhibitori hepatitisa c serin proteaze
SG161315A1 (en) Compounds and methods for the treatment or prevention of flavivirus infections
CU23787B7 (es) Compuestos macrocíclicos como inhibidores de la replicación viral
MY146123A (en) Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatment using the same
GEP20247600B (en) B-D-2'-DEOXY-2'a-FLUORO-2'-B-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
WO2011041713A3 (fr) Agents anti-viraux à base de pipérazinyle
TW200745035A (en) Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
HRP20110169T1 (hr) Upotreba [d-meala]3-[etval]4-ciklosporina za liječenje infekcija hepatitisom c
NO20074613L (no) Tricykliske nukleosidforbindelser for behandling av virale infeksjoner
DK1569929T3 (da) Forbindelser og fremgangsmåder til behandling eller forebyggelse af flavi-virusinfektioner
NZ587133A (en) Macrocyclic serine protease inhibitor compounds for treating an HCV infection
BR112014000563A2 (pt) composto, composição farmacêutica, e, uso do composto
TW200720285A (en) Nucleoside compounds for treating viral infections
MX2012008443A (es) Nucleosidos antiviricos.
TW200602064A (en) Nucleoside derivatives for treating hepatitis C virus infection
JP2010521481A5 (fr)
ATE455117T1 (de) 5,6-dimethylthienoä2,3-diüpyrimidinderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzung für die bekämpfung von viren
ME02682B (fr) Composés de pipérazine-pipéridine en tant qu'inhibiteurs du virus de l'hépatite c
ATE518861T1 (de) Als pestivirus-inhibitoren geeignete imidazoä1,2- aüpyrroloä3,2-cüpyridinverbindungen
JP2011517673A5 (fr)